test

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumors

Conditions

Breast - Female | Colon | Esophagus | Kidney | Liver | Lung | Melanoma, skin | Pancreas

What is the purpose of this trial?

This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in subjects with advanced solid tumors followed by an expansion phase in patients with advanced solid tumors.


Participation Guidelines

Age:
Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
MedImmune, Inc
Dates:
05/22/2014
Last Updated:
Study HIC#:
1403013517